Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Are currently receiving olaratumab and who, in consultation with their treating physician, want to continue their course of therapy.
Have metastatic or locally advanced unresectable soft tissue sarcoma not amenable to curative treatment with surgery or radiotherapy.
Have given written informed consent.
Have an absolute neutrophil count (ANC) ≥1,000/microliter.
Females of childbearing potential and males must agree to use highly effective contraceptive precautions during treatment with olaratumab and up to 3 months following the last dose of olaratumab. A highly effective method of birth control is defined as one that results in a low failure rate (that is, \<1% per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, some intrauterine contraceptive devices (IUDs), sexual abstinence, or a vasectomized partner.
You may not be if
Breastfeeding (patients who discontinue breastfeeding would be considered eligible).
Clareo Health | Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma
